EP0768872A1 - New oral pharmaceutical formulation containing magnesium salt of omeprazole - Google Patents
New oral pharmaceutical formulation containing magnesium salt of omeprazoleInfo
- Publication number
- EP0768872A1 EP0768872A1 EP95926067A EP95926067A EP0768872A1 EP 0768872 A1 EP0768872 A1 EP 0768872A1 EP 95926067 A EP95926067 A EP 95926067A EP 95926067 A EP95926067 A EP 95926067A EP 0768872 A1 EP0768872 A1 EP 0768872A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation according
- omeprazole
- formulation
- enteric
- enteric coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention is related to a new pharmaceutical formulation containing a novel physical form of a magnesium salt of omeprazole, to a method for the manufacture of such a formulation, and to the use of such a formulation in medicine.
- omeprazole From what is said about the stability properties of omeprazole, it is obvious that an oral dosage form of omeprazole must be protected from contact with the acid gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is near neutral and where rapid absorption of omeprazole can occur.
- the new pharmaceutical formulation is defined in claims 1-9, a process for the manufacture of the pharmaceutical formulation according to the present invention is defined in claims 10-11, the use of the formulation in medicine is defined in claims 12-18 and a press- through blister package is stated in claim 19.
- the powder mixture is then formulated into pellets, granules, beads or tablets by pharmaceutical procedures.
- the pellets, granules, beads or tablets are used as core material for further processing.
- the enteric coating layer is applied in one or more layers onto the formulated core material by coating procedures in suitable equipments such as pan coating, coating granulator or fluidized bed apparatus using solutions of polymers in water, or by using latex suspensions of said polymers or optionally using polymer solutions in suitable organic solvents.
- suitable equipments such as pan coating, coating granulator or fluidized bed apparatus using solutions of polymers in water, or by using latex suspensions of said polymers or optionally using polymer solutions in suitable organic solvents.
- enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer for example cetanol, triacetin, citric acid es- ters such as, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate, polyethylene glycol (PEG) or similar plasticizers.
- a pharmaceutically acceptable plasticizer for example cetanol, triacetin, citric acid es- ters such as, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate, polyethylene glycol (PEG) or similar plasticizers.
- Paraffin powder 0.05 Tablets with the composition described above have been manufactured in a laboratory scale of about 20 000 tablets.
- Amount omeprazole 40 Ingredient (mg/tabl.) ⁇
- Magnesium omeprazole, mannitol, hydroxypropyl methylcellulose, microcrystalline cellulose and sodium starch glycolate are dry-mixed, moistened with water and wet mixed. The wet mass is dried and milled and finally mixed with anti-adherent and lubricant substances. T e milled granulate is compressed to tablets with a diameter of 7 mm. The tablets are enteric coated with a methacrylic acid copolymer film.
- Enteric coated pellet formulation containing magnesium omeprazole being produced as described in WO95/01977.
- Non-pareil pellets 1.5 kg Hydroxypropyl methylcellulose 0.23 kg
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9400679 | 1994-07-08 | ||
WOPCT/SE94/00679 | 1994-07-08 | ||
PCT/SE1995/000816 WO1996001622A1 (en) | 1994-07-08 | 1995-07-03 | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0768872A1 true EP0768872A1 (en) | 1997-04-23 |
Family
ID=20393105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95926067A Withdrawn EP0768872A1 (en) | 1994-07-08 | 1995-07-05 | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0768872A1 (cs) |
KR (1) | KR970704426A (cs) |
BR (1) | BR9508261A (cs) |
CA (1) | CA2193681A1 (cs) |
CZ (1) | CZ379596A3 (cs) |
EE (1) | EE03378B1 (cs) |
FI (1) | FI970058A (cs) |
HU (1) | HUT78132A (cs) |
IS (1) | IS4398A (cs) |
MX (1) | MX9700152A (cs) |
NO (1) | NO970036D0 (cs) |
NZ (1) | NZ289958A (cs) |
PL (1) | PL181265B1 (cs) |
SK (1) | SK166096A3 (cs) |
WO (1) | WO1996001622A1 (cs) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5900258A (en) * | 1996-02-01 | 1999-05-04 | Zeolitics Inc. | Anti-bacterial compositions |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
EP1133987A1 (en) * | 2000-03-09 | 2001-09-19 | Ian Whitcroft | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
CA2413923A1 (en) * | 2000-03-09 | 2001-09-13 | Andrew Ilchyshyn | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
CA2771725C (en) | 2002-10-16 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Solid preparation comprising a non-toxic base and a proton pump inhibitor |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
EP1755566A2 (en) * | 2004-06-15 | 2007-02-28 | Teva Pharmaceutical Industries Ltd | Stable pharmaceutical formulations of benzimidazole compounds |
CN105106168B (zh) * | 2015-08-19 | 2018-03-06 | 德州德药制药有限公司 | 一种埃索美拉唑镁肠胶囊及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
-
1995
- 1995-07-03 BR BR9508261A patent/BR9508261A/pt not_active Application Discontinuation
- 1995-07-03 CA CA002193681A patent/CA2193681A1/en not_active Abandoned
- 1995-07-03 EE EE9700014A patent/EE03378B1/xx not_active IP Right Cessation
- 1995-07-03 MX MX9700152A patent/MX9700152A/es unknown
- 1995-07-03 HU HU9700039A patent/HUT78132A/hu unknown
- 1995-07-03 WO PCT/SE1995/000816 patent/WO1996001622A1/en not_active Application Discontinuation
- 1995-07-05 CZ CZ963795A patent/CZ379596A3/cs unknown
- 1995-07-05 KR KR1019970700059A patent/KR970704426A/ko not_active Application Discontinuation
- 1995-07-05 PL PL95318464A patent/PL181265B1/pl unknown
- 1995-07-05 EP EP95926067A patent/EP0768872A1/en not_active Withdrawn
- 1995-07-05 NZ NZ289958A patent/NZ289958A/en unknown
- 1995-07-05 SK SK1660-96A patent/SK166096A3/sk unknown
-
1996
- 1996-12-17 IS IS4398A patent/IS4398A/is unknown
-
1997
- 1997-01-06 NO NO970036A patent/NO970036D0/no not_active Application Discontinuation
- 1997-01-07 FI FI970058A patent/FI970058A/fi unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9601622A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2994795A (en) | 1996-02-09 |
HU9700039D0 (en) | 1997-02-28 |
PL318464A1 (en) | 1997-06-09 |
IS4398A (is) | 1996-12-17 |
BR9508261A (pt) | 1997-12-23 |
CA2193681A1 (en) | 1996-01-25 |
CZ379596A3 (en) | 1997-08-13 |
KR970704426A (ko) | 1997-09-06 |
HUT78132A (hu) | 2000-06-28 |
NZ289958A (en) | 1998-09-24 |
FI970058A0 (fi) | 1997-01-07 |
MX9700152A (es) | 1997-04-30 |
FI970058A (fi) | 1997-01-07 |
NO970036L (no) | 1997-01-06 |
EE03378B1 (et) | 2001-04-16 |
WO1996001622A8 (en) | 1999-12-23 |
PL181265B1 (pl) | 2001-06-29 |
WO1996001622A1 (en) | 1996-01-25 |
SK166096A3 (en) | 1997-09-10 |
EE9700014A (et) | 1997-06-16 |
NO970036D0 (no) | 1997-01-06 |
AU695723B2 (en) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5690960A (en) | Pharmaceutical formulation of omeprazole | |
CA2290531C (en) | Pharmaceutical formulation of omeprazole | |
EP0502556B1 (en) | Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds | |
EP0723436B1 (en) | Multiple unit tableted dosage form i | |
KR100384961B1 (ko) | 프로톤펌프억제제를함유하는다단위제약제제 | |
AU774278B2 (en) | Pharmaceutical formulation comprising omeprazole | |
EP0941074B1 (en) | Delayed delivery system for acid-sensitive drugs | |
EP0768872A1 (en) | New oral pharmaceutical formulation containing magnesium salt of omeprazole | |
AU695723C (en) | New oral pharmaceutical formulation containing magnesium salt of omeprazole | |
JP2023543252A (ja) | 腸溶性ペレット及びその製造方法並びにそれを含む製剤 | |
RU2173995C2 (ru) | Лекарственный препарат для перорального введения, содержащий магниевую соль омепразола | |
JPH10504288A (ja) | オメプラゾールのマグネシウム塩を含有する新規な経口医薬処方物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970210 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 970210;LV PAYMENT 970210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ASTRAZENECA AB |
|
17Q | First examination report despatched |
Effective date: 20001113 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010324 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1008297 Country of ref document: HK |